regulators

Coverage parity for mental health, substance abuse, a key focus for insurance regulators

Health insurers are prohibited from placing unfavorable limits on mental health and substance abuse benefits, and yet, many do. Federal and state regulators are taking aim at these practices and making the enforcement of the Mental Health Parity and Addiction Equity Act of 2008 a key focus.

By Anuja Vaidya

BioPharma

What can biotech companies learn from banking scandals?

A board stacked with well-known names but little hands-on knowledge suggests that governance is not a high priority and should ring warning bells for investors.

By Shanny Basar

BioPharma

BioLabs Pegasus Park Cultivates Life Science Ecosystem

Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

By PurpleLab

Coverage parity for mental health, substance abuse, a key focus for insurance regulators

What can biotech companies learn from banking scandals?

A Personalized Approach to Medication Nonadherence